dimethyldodecylbenzylammonium profile

Dimethyldodecylbenzylammonium chloride, also known as dodecylbenzyldimethylammonium chloride, is a quaternary ammonium compound with the chemical formula C21H38ClN. It is a cationic surfactant and is commonly used as an antimicrobial agent in various applications, including disinfectants, sanitizers, and personal care products. The synthesis of dimethyldodecylbenzylammonium chloride typically involves the reaction of dodecylbenzene with dimethylamine in the presence of a catalyst, followed by alkylation with chloromethyl ether. The compound is known for its bactericidal, fungicidal, and virucidal properties. Its efficacy is attributed to its ability to disrupt cell membranes and interfere with the functions of essential enzymes. Due to its antimicrobial activity, dimethyldodecylbenzylammonium chloride is extensively studied for its potential to combat bacterial infections, particularly those caused by multidrug-resistant strains. Research focuses on optimizing its synthesis and formulation, exploring its efficacy against specific pathogens, and evaluating its safety and environmental impact.'

benzododecinium bromide : The organic bromide salt of benzododecinium. It is a cationic surfactant that has antispetic and disinfectant properties. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

dimethyldodecylbenzylammonium: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

benzododecinium : A quaternary ammonium ion obtained by methylation of N-benzyl-N-methyldodecan-1-amine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	23705
CHEMBL ID	2355417
CHEBI ID	167207
SCHEMBL ID	119589
MeSH ID	M0064248
PubMed CID	8754
CHEMBL ID	1907001
CHEBI ID	135611
SCHEMBL ID	153696
MeSH ID	M0064248

Synonym
einecs 230-698-4
sinnoquat bl 80
benzalkonium bromide
dodecyl dimethyl benzyl ammonium bromide
ammonium, benzyldodecyldimethyl-, bromide
dimethyl laurylbenzene ammonium bromide
epa pesticide chemical code 069123
n-dodecyl-n,n-dimethylbenzenemethanaminium bromide
benzododecinium bromatum
benzododecinium bromide
ammonyl br 1244
caswell no. 416b
bromek dwumetylolaurylobenzyloamoniowy [polish]
benzenemethanaminium, n-dodecyl-n,n-dimethyl-, bromide
lauralkonium bromide
bacfor bl
sinnoquat bl 95
n-benzyl-n,n-dimethyldodecan-1-aminium bromide
CHEBI:167207 ,
7281-04-1
dimethyldodecylbenzylammonium bromide
benzyldodecyldimethylammonium bromide
benzyldimethyldodecylammonium bromide
sterinol
B3748
dtxsid4048698 ,
cas-7281-04-1
tox21_113091
dtxcid4028624
8043-47-8
iry12b2tq6 ,
benzenemethanaminium, n-dodecyl-n,n-dimethyl-, bromide (1:1)
bromek dwumetylolaurylobenzyloamoniowy
unii-iry12b2tq6
91080-29-4
benzododecinium bromide [who-dd]
benzododecinium bromide [mart.]
lauralkonium bromide [inci]
benzododecinium bromide [ii]
AKOS015891185
SCHEMBL119589
tox21_113091_1
NCGC00164245-03
CHEMBL2355417
Q-200699
mfcd00011768
n-benzyl-n,n-dimethyldodecan-1-amonium bromide
benzyl-dodecyldimethylammonium bromide
benzyl-dodecyl-dimethylazanium;bromide
FT-0733931
Q4890794
benzalkonium bromide (c12)
D87631
benzyl(dodecyl)dimethylazanium bromide
benzalkonium bromide dimethyl benzyl lauryl ammonium bromide
BS-44064
n-benzyl-n,n-dimethyldodecan-1-aminiumbromide
n-benzyl-n,n-dimethyldodecan-1-ammonium bromide
CS-0152236
benzododecinium bromure
benzododecinium bromide (mart.)
benzododecinium bromide (ii)
youjie weishi antibacterial hand wash
HY-W099594
STL301825
nsc-9660
5459-84-7
nsc-9658
nsc9660
nsc9658
benzenemethanaminium, n-dodecyl-n,n-dimethyl-
benzyldimethyldodecylammonium ion
n-dodecyl-n,n-dimethylbenzenemethanaminium
dimethyllaurylbenzylammonium
ammonium, benzyldodecyldimethyl-
benzododecinium
benzyldodecyldimethylammonium
n-benzyl-n-dodecyl-n,n-dimethylammonium
ajatin
lauryldimethylbenzylammonium
dimethyldodecylbenzylammonium
CHEBI:135611 ,
benzyl-dodecyl-dimethylazanium
1340-95-0
n-benzyl-n,n-dimethyldodecan-1-aminium
NCGC00164245-02
10328-35-5
n0bn0o8csl ,
unii-n0bn0o8csl
benzododecinium cation
benzododecinium ion
benzododecinium [who-dd]
AKOS022105931
SCHEMBL153696
CHEMBL1907001
DTXSID60872947
SR-01000944376-1
sr-01000944376
benzalkonium chloride c12
benzyldodecyldimethylammoniumbromide
DB13282
benzalkonium chloride (c12)
Q27284345
n-benzyl-n,n-dimethyl-1-dodecanaminium
dodecyldimethyl(benzyl)aminium
n,n-dimethyl-n-benzyl-1-dodecanaminium
dimethyl(benzyl)(dodecyl)aminium
benzyl(dodecyl)dimethylazanium
n,n-dimethyl-n-benzyldodecan-1-aminium

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
"Animals dosed orally with nitrite (1."	( Nitrosation of quaternary ammonium compounds in vivo in the Wistar rat. Maduagwu, EN, 1985)	0.27
"The factors which markedly influence availability of the drug from the dosage form include also auxiliary substances, which are an inevitable component in the formulation of the drug."	( [Preformulation studies of potential drug XIX M: partition coefficient]. Capková, Z; Cizmárik, J; Tilandyová, J; Vitková, Z, 2005)	0.33

Role	Description
surfactant	A substance which lowers the surface tension of the medium in which it is dissolved, and/or the interfacial tension with other phases, and, accordingly, is positively adsorbed at the liquid/vapour and/or at other interfaces.
antiseptic drug	A substance used locally on humans and other animals to destroy harmful microorganisms or to inhibit their activity (cf. disinfectants, which destroy microorganisms found on non-living objects, and antibiotics, which can be transported through the lymphatic system to destroy bacteria within the body).
disinfectant	An antimicrobial agent that is applied to non-living objects to destroy harmful microorganisms or to inhibit their activity.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
quaternary ammonium salt	Derivatives of ammonium compounds, (NH4(+))Y(-), in which all four of the hydrogens bonded to nitrogen have been replaced with univalent (usually organyl) groups.
organic bromide salt
quaternary ammonium ion	A derivative of ammonium, NH4(+), in which all four of the hydrogens bonded to nitrogen have been replaced with univalent (usually organyl) groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
acetylcholinesterase	Homo sapiens (human)	Potency	28.6939	0.0025	41.7960	15,848.9004	AID1347395; AID1347397; AID1347398
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	6.7400	3.1890	29.8841	59.4836	AID1224846
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	21.1317	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
SMAD family member 2	Homo sapiens (human)	Potency	13.2791	0.1737	34.3047	61.8120	AID1346859; AID1346924
Fumarate hydratase	Homo sapiens (human)	Potency	35.4813	0.0030	8.7949	48.0869	AID1347053
SMAD family member 3	Homo sapiens (human)	Potency	13.2791	0.1737	34.3047	61.8120	AID1346859; AID1346924
TDP1 protein	Homo sapiens (human)	Potency	1.5876	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	2.2130	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	17.6172	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
caspase 7, apoptosis-related cysteine protease	Homo sapiens (human)	Potency	33.4915	0.0133	26.9810	70.7614	AID1346978
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	33.4915	0.0006	57.9133	22,387.1992	AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	31.6529	0.0010	22.6508	76.6163	AID1224838; AID1224839; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	31.6704	0.0004	17.9460	75.1148	AID1346784; AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	38.9018	0.0123	7.9835	43.2770	AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	18.0308	0.0002	14.3764	60.0339	AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	18.6759	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	1.5417	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	8.7658	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	32.2749	0.3758	27.4851	61.6524	AID743217; AID743220; AID743239
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	17.1473	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
G	Vesicular stomatitis virus	Potency	15.4871	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	0.1950	0.0010	8.3798	61.1304	AID1645840
polyprotein	Zika virus	Potency	35.4813	0.0030	8.7949	48.0869	AID1347053
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	30.7001	0.0010	24.5048	61.6448	AID743215; AID743227
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	29.1694	0.0010	19.4141	70.9645	AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	27.7124	0.0237	23.2282	63.5986	AID743222; AID743223; AID743241
caspase-3	Homo sapiens (human)	Potency	33.4915	0.0133	26.9810	70.7614	AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	29.8493	0.0017	23.8393	78.1014	AID743083
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	22.1917	0.0016	28.0151	77.1139	AID1224843; AID1224895
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	26.8325	19.7391	45.9784	64.9432	AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	26.8325	0.0578	21.1097	61.2679	AID1159526
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	60.1993	0.0391	47.5451	146.8240	AID1224845; AID1224896
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	5.2081	0.0003	23.4451	159.6830	AID743065; AID743067
heat shock protein beta-1	Homo sapiens (human)	Potency	31.6679	0.0420	27.3789	61.6448	AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	33.4889	0.0006	27.2152	1,122.0200	AID743202
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	5.9557	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	24.3905	0.0033	9.1582	39.8107	AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	15.4871	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	25.4905	0.0023	19.5956	74.0614	AID651631; AID720552
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	5.9557	0.0015	51.7393	15,848.9004	AID1259244
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	15.4871	0.0123	8.9648	39.8107	AID1645842
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	10.2744	0.0119	17.9420	71.5630	AID651632; AID720516
Ataxin-2	Homo sapiens (human)	Potency	13.3332	0.0119	12.2221	68.7989	AID651632
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	15.4871	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cell population proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of B cell proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nuclear DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
signal transduction in response to DNA damage	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
isotype switching	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of isotype switching to IgG isotypes	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloading	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of cell cycle G2/M phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (127)

Assay ID	Title	Year	Journal	Article
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1272717	Antimicrobial activity against Candida albicans ATCC 44859 after 48 hrs by spectrophotometry	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1612863	Induction of morphological changes in Staphylococcus aureus ATCC 29213 assessed as cell wall damage at MIC after 1 hr by atomic force microscopic analysis	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of novel quaternary ammonium compounds based on quinuclidine-3-ol as new potential antimicrobial candidates.
AID1172724	Antibacterial activity against Staphylococcus aureus H 5996/08 after 48 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272725	Antimicrobial activity against Trichosporon asahii 1188 after 48 hrs by spectrophotometry	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1272727	Antimicrobial activity against Absidia corymbifera 272 after 24 hrs by spectrophotometry	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1172745	Antifungal activity against Candida albicans ATCC 44859 after 48 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172756	Antifungal activity against Trichosporon asahii 1188 after 24 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172721	Antibacterial activity against Staphylococcus aureus CCM 4516/08 after 48 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172759	Antifungal activity against Aspergillus fumigatus 231 after 24 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172751	Antifungal activity against Candida krusei E28 after 48 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272714	Antimicrobial activity against clinical isolate Pseudomonas aeruginosa CCM 1961 after 120 hrs	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1272722	Antimicrobial activity against Candida glabrata 20/I after 24 hrs by spectrophotometry	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1272701	Antimicrobial activity against clinical isolate methicillin-resistant Staphylococcus aureus H 599608 after 24 hrs	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1272708	Antimicrobial activity against clinical isolate Escherichia coli CCM 4517 after 48 hrs	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1172734	Bactericidal activity against Escherichia coli CCM 4517 after 48 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272728	Antimicrobial activity against Absidia corymbifera 272 after 48 hrs by spectrophotometry	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1272723	Antimicrobial activity against Candida glabrata 20/I after 48 hrs by spectrophotometry	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1172760	Antifungal activity against Aspergillus fumigatus 231 after 48 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272706	Antimicrobial activity against clinical isolate Enterococcus sp. J 1436508 after 48 hrs	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1172738	Antibacterial activity against Klebsiella pneumoniae J 14368/08 after 24 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272721	Antimicrobial activity against Candida krusei E28 after 48 hrs by spectrophotometry	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1272726	Antimicrobial activity against Aspergillus fumigatus 231 after 48 hrs by spectrophotometry	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1172735	Antibacterial activity against Klebsiella pneumoniae D 11750/08 after 24 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272710	Antimicrobial activity against clinical isolate Klebsiella pneumoniae D 1175008 after 48 hrs	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1272716	Antimicrobial activity against Aspergillus fumigatus 231 after 24 hrs by spectrophotometry	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1172746	Fungicidal activity against Candida albicans ATCC 44859 after 48 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172728	Bactericidal activity against Staphylococcus epidermidis H 6966/08 after 48 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172752	Fungicidal activity against Candida krusei E28 after 48 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272730	Antimicrobial activity against Trichophyton mentagrophytes 445 after 120 hrs by spectrophotometry	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1612875	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTS assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of novel quaternary ammonium compounds based on quinuclidine-3-ol as new potential antimicrobial candidates.
AID1172744	Antifungal activity against Candida albicans ATCC 44859 after 24 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172731	Bactericidal activity against Enterococcus sp. J 14365/08 after 48 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172767	Fungicidal activity against Trichophyton mentagrophytes 445 after 120 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1612852	Bactericidal activity against Escherichia coli ATCC 25922 preincubated for 24 to 48 hrs followed by replating on MHA plates and measured after 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of novel quaternary ammonium compounds based on quinuclidine-3-ol as new potential antimicrobial candidates.
AID1612847	Bactericidal activity against Staphylococcus aureus ATCC 29213 preincubated for 24 to 48 hrs followed by replating on MHA plates and measured after 18 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of novel quaternary ammonium compounds based on quinuclidine-3-ol as new potential antimicrobial candidates.
AID1172762	Antifungal activity against Absidia corymbifera 272 after 24 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272704	Antimicrobial activity against clinical isolate Staphylococcus epidermidis H 696608 after 48 hrs	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1272731	Cytotoxicity against CHOK1 cells after 24 hrs by MTT assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1272719	Antimicrobial activity against Candida tropicalis 156 after 48 hrs by spectrophotometry	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1172726	Antibacterial activity against Staphylococcus epidermidis H 6966/08 after 24 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172763	Antifungal activity against Absidia corymbifera 272 after 48 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272715	Antimicrobial activity against Candida albicans ATCC 44859 after 24 hrs by spectrophotometry	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1612831	Antimicrobial activity against Staphylococcus aureus ATCC 29213 after 24 to 48 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of novel quaternary ammonium compounds based on quinuclidine-3-ol as new potential antimicrobial candidates.
AID1172750	Antifungal activity against Candida krusei E28 after 24 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172743	Bactericidal activity against Pseudomonas aeruginosa CCM 1961 after 120 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172723	Antibacterial activity against Staphylococcus aureus H 5996/08 after 24 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272712	Antimicrobial activity against clinical isolate ESBL-Klebsiella pneumoniae J 1436808 after 48 hrs	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1272702	Antimicrobial activity against clinical isolate methicillin-resistant Staphylococcus aureus H 599608 after 48 hrs	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1172757	Antifungal activity against Trichosporon asahii 1188 after 48 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172747	Antifungal activity against Candida tropicalis 156 after 24 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1612874	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTS assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of novel quaternary ammonium compounds based on quinuclidine-3-ol as new potential antimicrobial candidates.
AID1172733	Antibacterial activity against Escherichia coli CCM 4517 after 48 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172741	Antibacterial activity against Pseudomonas aeruginosa CCM 1961 after 72 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172720	Antibacterial activity against Staphylococcus aureus CCM 4516/08 after 24 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272700	Antimicrobial activity against clinical isolate Staphylococcus aureus CCM 451608 after 48 hrs	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1172753	Antifungal activity against Candida glabrata 20/I after 24 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172768	Cytotoxicity against CHOK1 cells after 24 hrs by MTT assay	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272703	Antimicrobial activity against clinical isolate Staphylococcus epidermidis H 696608 after 24 hrs	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1172739	Antibacterial activity against Klebsiella pneumoniae J 14368/08 after 48 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172761	Fungicidal activity against Aspergillus fumigatus 231 after 48 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172727	Antibacterial activity against Staphylococcus epidermidis H 6966/08 after 48 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172732	Antibacterial activity against Escherichia coli CCM 4517 after 24 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172736	Antibacterial activity against Klebsiella pneumoniae D 11750/08 after 48 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272707	Antimicrobial activity against clinical isolate Escherichia coli CCM 4517 after 24 hrs	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1172729	Antibacterial activity against Enterococcus sp. J 14365/08 after 24 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172742	Antibacterial activity against Pseudomonas aeruginosa CCM 1961 after 120 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272724	Antimicrobial activity against Trichosporon asahii 1188 after 24 hrs by spectrophotometry	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1272718	Antimicrobial activity against Candida tropicalis 156 after 24 hrs by spectrophotometry	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1172722	Bactericidal activity against Staphylococcus aureus CCM 4516/08 after 48 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272711	Antimicrobial activity against clinical isolate ESBL-Klebsiella pneumoniae J 1436808 after 24 hrs	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1272709	Antimicrobial activity against clinical isolate Klebsiella pneumoniae D 1175008 after 24 hrs	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1612836	Antimicrobial activity against Escherichia coli ATCC 25922 after 24 to 48 hrs by broth microdilution assay	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of novel quaternary ammonium compounds based on quinuclidine-3-ol as new potential antimicrobial candidates.
AID1272713	Antimicrobial activity against clinical isolate Pseudomonas aeruginosa CCM 1961 after 72 hrs	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1172730	Antibacterial activity against Enterococcus sp. J 14365/08 after 48 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172740	Bactericidal activity against Klebsiella pneumoniae J 14368/08 after 48 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272699	Antimicrobial activity against clinical isolate Staphylococcus aureus CCM 451608 after 24 hrs	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1172725	Bactericidal activity against Staphylococcus aureus H 5996/08 after 48 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272720	Antimicrobial activity against Candida krusei E28 after 24 hrs by spectrophotometry	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1172764	Fungicidal activity against Absidia corymbifera 272 after 48 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172766	Antifungal activity against Trichophyton mentagrophytes 445 after 120 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172755	Fungicidal activity against Candida glabrata 20/I after 48 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172765	Antifungal activity against Trichophyton mentagrophytes 445 after 72 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172754	Antifungal activity against Candida glabrata 20/I after 48 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1272729	Antimicrobial activity against Trichophyton mentagrophytes 445 after 72 hrs by spectrophotometry	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1272705	Antimicrobial activity against clinical isolate Enterococcus sp. J 1436508 after 24 hrs	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Synthesis, antimicrobial evaluation and molecular modeling of 5-hydroxyisoquinolinium salt series; the effect of the hydroxyl moiety.
AID1172748	Antifungal activity against Candida tropicalis 156 after 48 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172737	Bactericidal activity against Klebsiella pneumoniae D 11750/08 after 24 hrs by microdilution broth method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172758	Fungicidal activity against Trichosporon asahii 1188 after 48 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1172749	Fungicidal activity against Candida tropicalis 156 after 48 hrs by modified standard CSLI M27-A2 method	2014	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22	6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1145368	Antimicrobial activity against Pseudomonas aeruginosa	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Molecular connectivity. 6. Examination of the parabolic relationship between molecular connectivity and biological activity.
AID1145369	Antimicrobial activity against Staphylococcus aureus	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Molecular connectivity. 6. Examination of the parabolic relationship between molecular connectivity and biological activity.
AID1145371	Toxicity in sheep RBC assessed as hemolysis	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Molecular connectivity. 6. Examination of the parabolic relationship between molecular connectivity and biological activity.
AID1145370	Antimicrobial activity against Clostridium welchii	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Molecular connectivity. 6. Examination of the parabolic relationship between molecular connectivity and biological activity.
AID1149264	Antimicrobial activity against Staphylococcus aureus	1976	Journal of medicinal chemistry, May, Volume: 19, Issue:5	Quantitative structure-activity relationships. 2. A mixed approach, based on Hansch and Free-Wilson Analysis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	20 (31.25)	18.7374
1990's	12 (18.75)	18.2507
2000's	9 (14.06)	29.6817
2010's	15 (23.44)	24.3611
2020's	8 (12.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Trials	3 (5.26%)	5.53%
Reviews	0 (0.00%)	6.00%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	3 (5.26%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	0 (0.00%)	0.25%
Other	12 (100.00%)	84.16%
Other	51 (89.47%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
sterogenol hexadecylpyridinium bromide: structure in first source. cetylpyridinium bromide : A pyridinium salt that has N-hexadecylpyridinium as the cation and bromide as the anion.	2.1	1	0	bromide salt; pyridinium salt	antiseptic drug; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; surfactant
3-quinuclidinol quinuclidin-3-Ol: structure in first source	2.21	1	0	quinuclidines; secondary alcohol; tertiary amine
laurosept Laurosept: RN given refers to bromide	2.1	1	0
bromide Bromides: Salts of hydrobromic acid, HBr, with the bromine atom in the 1- oxidation state. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)	1.98	1	0	halide anion; monoatomic bromine
carbamates [no description available]	2.02	1	0	amino-acid anion
2-cresol 2-cresol: RN given refers to parent cpd. o-cresol : A cresol that is phenol substituted by a methyl group at position 2. It is a minor urinary metabolite of toluene.	1.95	1	0	cresol	human xenobiotic metabolite
salicylic acid Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).	2.03	1	0	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
3-cresol 3-cresol: RN given refers to parent cpd. m-cresol : A cresol with the methyl substituent at position 3. It is a minor urinary metabolite of toluene.	2.66	3	0	cresol	human xenobiotic metabolite
formaldehyde paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy	2.9	4	0	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
nitrites Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)	1.96	1	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
phenol [no description available]	1.95	1	0	phenols	antiseptic drug; disinfectant; human xenobiotic metabolite; mouse metabolite
chlorocresol chlorocresol: injections for relief of intractable pain; RN given refers to parent cpd. 4-chloro-m-cresol : A hydroxytoluene that is 3-methylphenol which is substituted by a chlorine at position 4. A ryanodine receptor agonist.	1.95	1	0	hydroxytoluene; monochlorobenzenes	antimicrobial agent; disinfectant; ryanodine receptor agonist
acetochlor acetochlor : A monocarboxylic acid amide that is N-phenylacetamide carrying an ethyl and a methyl group at positions 2 and 6 respectively on the benzene ring while one of the methyl hydrogens as well as the hydrogen attached to the nitrogen atom have been replaced by a chloro and an ethoxymethyl group respectively.	2.02	1	0	aromatic amide; monocarboxylic acid amide; organochlorine compound	environmental contaminant; herbicide; xenobiotic
amobarbital Amobarbital: A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565). amobarbital : A member of the class of barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by a 3-methylbutyl and an ethyl group at position 5. Amobarbital has been shown to exhibit sedative and hypnotic properties.	1.95	1	0	barbiturates
barbital 5,5-diethylbarbituric acid : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by two ethyl groups. Formerly used as a hypnotic (sleeping aid).	1.95	1	0	barbiturates	drug allergen
secbutabarbital secbutabarbital: Butabarbital (a synonym for Secbutabarbital) should be distinguished from Butobarbital	1.95	1	0	barbiturates
butalbital butalbital: management of butalbital withdrawal can be simplified by using a phenobarbital-loading protocol; RN given refers to parent cpd. butalbital : A member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. Frequently combined with other medicines, such as aspirin, paracetamol and codeine, it is used for treatment of pain and headache.	1.95	1	0	barbiturates	analgesic; sedative
cetyltrimethylammonium ion Cetrimonium: Cetyltrimethylammonium compound whose salts and derivatives are used primarily as topical antiseptics.. cetyltrimethylammonium ion : A quaternary ammonium ion in which the substituents on nitrogen are one hexadecyl and three methyl groups.	2.66	3	0	quaternary ammonium ion
cetylpyridinium Cetylpyridinium: Cationic bactericidal surfactant used as a topical antiseptic for skin, wounds, mucous membranes, instruments, etc.; and also as a component in mouthwash and lozenges.	2.37	2	0	pyridinium ion
chloroxylenol chloroxylenol: topical antiseptic; RN given refers to parent cpd; structure. 4-chloro-3,5-dimethylphenol : A member of the class of phenols that is 3,5-xylenol which is substituted at position 4 by chlorine. It is bactericidal against most Gram-positive bacteria but less effective against Staphylococci and Gram-negative bacteria, and often inactive against Pseudomonas species. It is ineffective against bacterial spores.	1.95	1	0	monochlorobenzenes; phenols	antiseptic drug; disinfectant; molluscicide
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	2.03	1	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
glutaral Glutaral: One of the protein CROSS-LINKING REAGENTS that is used as a disinfectant for sterilization of heat-sensitive equipment and as a laboratory reagent, especially as a fixative.. glutaraldehyde : A dialdehyde comprised of pentane with aldehyde functions at C-1 and C-5.	2.68	3	0	dialdehyde	cross-linking reagent; disinfectant; fixative
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	3.44	1	1	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
4-chlorophenol 4-chlorophenol: used as a root canal irrigant. 4-chlorophenol : A monochlorophenol substituted at the pare position by a chlorine atom.	1.95	1	0	monochlorophenol
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	1.95	1	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
urethane [no description available]	1.95	1	0	carbamate ester	fungal metabolite; mutagen
thyroxine Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.	1.95	1	0	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
allobarbital allobarbital: was heading 1976-94 (see under BARBITURATES 1976-90); ALLOBARBITONE, DIALLYLBARBITAL, DIALLYLBARBITURIC ACID, & DIALLYLMAL were see ALLOBARBITAL 1976-94; use BARBITURATES to search ALLOBARBITAL 1976-94; a barbiturate derivative with effects of intermediate duration; at lower doses, it is used as a sedative; at higher doses, it displays hypnotic effects	1.95	1	0	barbiturates
triiodothyronine Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.	1.95	1	0	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone
phenylephrine Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.	1.96	1	0	phenols; phenylethanolamines; secondary amino compound	alpha-adrenergic agonist; cardiotonic drug; mydriatic agent; nasal decongestant; protective agent; sympathomimetic agent; vasoconstrictor agent
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	1.98	1	0	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
trichloroacetic acid Trichloroacetic Acid: A strong acid used as a protein precipitant in clinical chemistry and also as a caustic for removing warts.. trichloroacetic acid : A monocarboxylic acid that is acetic acid in which all three methyl hydrogens are substituted by chlorine.	2.13	1	0	monocarboxylic acid; organochlorine compound	carcinogenic agent; metabolite; mouse metabolite
allylpropymal allylpropymal: RN given refers to parent cpd. aprobarbital : A member of the class of barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by an isopropyl and a prop-1-en-3-yl group at position 5.	1.95	1	0	barbiturates
butobarbital butobarbital: Butobarbital should be distinguished from Butabarbital (a synonym for Secbutabarbital)	1.95	1	0	barbiturates
peracetic acid Peracetic Acid: A liquid that functions as a strong oxidizing agent. It has an acrid odor and is used as a disinfectant.. peracetic acid : A peroxy acid that is acetic acid in which the OH group is substituted by a hydroperoxy group. It is a versatile oxidising agent that is used as a disinfectant.	2.68	3	0	a peroxy acid	disinfectant; oxidising agent
2-isopropylphenol 2-isopropylphenol: structure given in first source. 2-isopropylphenol : A member of the class of phenols carrying an isopropyl group at position 2.	1.95	1	0	phenols
2-phenylphenol 2-phenylphenol: RN given refers to parent cpd; structure. biphenyl-2-ol : A member of the class of hydroxybiphenyls that is biphenyl substituted by a hydroxy group at position 2. It is generally used as a post-harvest fungicide for citrus fruits.	1.95	1	0	hydroxybiphenyls	antifungal agrochemical; environmental food contaminant
4-anisidine 4-anisidine: RN given refers to parent cpd. p-anisidine : A substituted aniline that is aniline in which the hydrogen para to the amino group has been replaced by a methoxy group. It is used as a reagent for the detection of oxidation products such as aldehydes and ketones in fats and oils.	1.95	1	0	methoxybenzenes; primary amino compound; substituted aniline	genotoxin; reagent
3,5-xylenol 3,5-xylenol: RN given refers to 3,5-isomer. 3,5-xylenol : A member of the class of phenols that phenol substituted by methyl groups at positions 3 and 5.	1.95	1	0	phenols	xenobiotic metabolite
talbutal [no description available]	1.95	1	0	barbiturates
framycetin Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.	1.97	1	0	aminoglycoside	allergen; antibacterial drug; Escherichia coli metabolite
phenetidine Phenetidine: Used in the manufacture of acetophenetidin.. 4-ethoxyaniline : An aromatic ether that is aniline in which the hydrogen at position 4 is replaced by an ethoxy group. It is a hydrolysis metabolite of phenacetin.	1.95	1	0	aromatic ether; primary amino compound; substituted aniline	drug metabolite
neutral red Neutral Red: A vital dye used as an indicator and biological stain. Various adverse effects have been observed in biological systems.. neutral red : A hydrochloride obtained by combining the free base of neutral red with one equivalent of hydrochloric acid. Neutral red acts as a pH indicator, changing from red to yellow between pH 6.8 and 8.0.	2	1	0	hydrochloride	acid-base indicator; dye; two-colour indicator
2,6-xylenol [no description available]	1.95	1	0	hydroxytoluene
levulinic acid levulinic acid: inhibits 5-aminolevulinic acid dehydratase; RN given refers to parent cpd; structure in Merck Index, 9th ed, #5316. 4-oxopentanoic acid : An oxopentanoic acid with the oxo group in the 4-position.	2.6	1	0	oxopentanoic acid; straight-chain saturated fatty acid	plant metabolite
methyl carbamate methyl carbamate : A carbamate ester resulting from the formal condensation of the carboxy group of carbamic acid with methanol.	1.95	1	0	carbamate ester
4-chloro-2-cresol 4-chloro-2-cresol: metabolite of 2-methyl-4-chlorophenoxyacetic acid & other phenoxyacetic acid herbicides; RN given refers to parent cpd. 4-chloro-2-methylphenol : A member of the class of phenols that is o-cresol in which the hydrogen para to the hydroxy group is replaced by a chlorine.	1.95	1	0	monochlorobenzenes; phenols
chloramine [no description available]	2.38	2	0	halide
ammonium chloride Ammonium Chloride: An acidifying agent that has expectorant and diuretic effects. Also used in etching and batteries and as a flux in electroplating.. ammonium chloride : An inorganic chloride having ammonium as the counterion.	3.14	1	0	ammonium salt; inorganic chloride	ferroptosis inhibitor
cromolyn sodium Cromolyn Sodium: A chromone complex that acts by inhibiting the release of chemical mediators from sensitized MAST CELLS. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack.. disodium cromoglycate : An organic sodium salt that is the disodium salt of cromoglycic acid.	1.96	1	0	organic sodium salt	anti-asthmatic drug; drug allergen
cetalkonium chloride cetalkonium chloride: Note: Bonjela is a multimeaning drug name.	2.03	1	0
n,n-dimethyl-n-octadecylbenzylammonium N,N-dimethyl-N-octadecylbenzylammonium: RN given refers to parent cpd	2.35	2	0
4-hexyloxyaniline [no description available]	1.95	1	0	aromatic ether; substituted aniline
imazaquin imazaquin: RN given refer to parent cpd. imazaquin : A racemate comprising equimolar amounts of (R)- and (S)-imazaquin. It is a pre- and post-emergence herbicide used for the control of grasses and broad-leaved weeds.. 2-[4-methyl-5-oxo-4-(propan-2-yl)-4,5-dihydro-1H-imidazol-2-yl]quinoline-3-carboxylic acid : A quinolinemonocarboxylic acid that is quinoline-3-carboxylic acid which is substituted by a 4-methyl-5-oxo-4-(propan-2-yl)-4,5-dihydro-1H-imidazol-2-yl group at position 2.	2.02	1	0	imidazolone; monocarboxylic acid; quinolinemonocarboxylic acid
laurosept Laurosept: RN given refers to bromide	1.95	1	0
phenyl methacrylate phenyl methacrylate: structure in first source	1.95	1	0
sulfosulfuron [no description available]	2.02	1	0
3,5-diiodothyronine, (l)-isomer [no description available]	1.95	1	0	phenylalanine derivative
3,5-dimethyl-3'-isopropyl-l-thyronine 3,5-dimethyl-3'-isopropyl-L-thyronine: RN given refers to (L)-isomer	1.95	1	0
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	3.44	1	1	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
septonex Septonex: RN given refers to bromide	2.86	4	0
cyclotriveratrylene cyclotriveratrylene: structure in first source	2.13	1	0
glycogen glycogen : A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.	1.95	1	0
amylopectin Amylopectin: A highly branched glucan in starch.. amylopectin : A polydisperse highly branched polysaccharide derivative composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage. The chains are joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some 6-phosphate ester groups also may occur. The branches in amylopectin typically contain 24 to 30 glucose residues.	1.95	1	0
farnesol Farnesol: A colorless liquid extracted from oils of plants such as citronella, neroli, cyclamen, and tuberose. It is an intermediate step in the biological synthesis of cholesterol from mevalonic acid in vertebrates. It has a delicate odor and is used in perfumery. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). (2-trans,6-trans)-farnesol : The (2-trans,6-trans)-stereoisomer of farnesol.. farnesol : A farnesane sesquiterpenoid that is dodeca-2,6,10-triene substituted by methyl groups at positions 3, 7 and 11 and a hydroxy group at position 1.	1.98	1	0	farnesol	plant metabolite
oleic acid Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.	2.03	1	0	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
flavin-adenine dinucleotide Flavin-Adenine Dinucleotide: A condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase. (Lehninger, Principles of Biochemistry, 1982, p972)	1.98	1	0	flavin adenine dinucleotide; vitamin B2	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; prosthetic group
sodium dodecyl sulfate Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.	2.11	1	0	organic sodium salt	detergent; protein denaturant
crocin crocin: a free radical scavenger	2.6	1	0
chloramine-t chloramine-T: RN given refers to unlabeled parent cpd. chloramine T : An organic sodium salt derivative of toluene-4-sulfonamide with a chloro substituent in place of an amino hydrogen.	2.68	3	0	organic sodium salt	allergen; antifouling biocide; disinfectant
chlorhexidine Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.	1.98	1	0	biguanides; monochlorobenzenes	antibacterial agent; antiinfective agent
lysol [no description available]	1.97	1	0	amino alcohol
phytosterols Phytosterols: A class of organic compounds known as sterols or STEROIDS derived from plants.. phytosterols : Sterols similar to cholesterol which occur in plants and vary only in carbon side chains and/or presence or absence of a double bond.	2.93	1	0
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	2.42	2	0	1,2-diacyl-sn-glycero-3-phosphocholine
chitosan [no description available]	2.21	1	0
chrome azurol s chrome azurol S: reagent for beryllium determination spectrophotometrically	1.95	1	0
formocresol formocresol: preferred agent for performing pulpotomies in primary teeth	1.96	1	0

Condition	Relationship Strength	Studies	Trials
Congenital Zika Syndrome [description not available]	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1	0
Extravascular Hemolysis [description not available]	1.95	1	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	1.95	1	0
Candida Infection [description not available]	1.93	1	0
Dermatophytoses [description not available]	1.93	1	0
Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)	1.93	1	0
Tinea Fungal infection of keratinized tissues such as hair, skin and nails. The main causative fungi include MICROSPORUM; TRICHOPHYTON; and EPIDERMOPHYTON.	1.93	1	0
Encephalomyelitis, Inflammatory [description not available]	1.94	1	0
Vaccinia The cutaneous and occasional systemic reactions associated with vaccination using smallpox (variola) vaccine.	1.94	1	0
Encephalitis, Equine [description not available]	1.94	1	0
Encephalomyelitis A general term indicating inflammation of the BRAIN and SPINAL CORD, often used to indicate an infectious process, but also applicable to a variety of autoimmune and toxic-metabolic conditions. There is significant overlap regarding the usage of this term and ENCEPHALITIS in the literature.	1.94	1	0
Blood Diseases [description not available]	2.93	1	0
Hematologic Diseases Disorders of the blood and blood forming tissues.	2.93	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.02	1	0
Hospital-Acquired Condition [description not available]	1.96	1	0
Esophagitis INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.	1.96	1	0
Gastritis Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.	1.96	1	0
Asthma, Bronchial [description not available]	1.98	1	0
Diseases, Occupational [description not available]	1.98	1	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	1.98	1	0
Nasal Polyps Focal accumulations of EDEMA fluid in the NASAL MUCOSA accompanied by HYPERPLASIA of the associated submucosal connective tissue. Polyps may be NEOPLASMS, foci of INFLAMMATION, degenerative lesions, or malformations.	7.41	4	4
Blood Poisoning [description not available]	1.97	1	0
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	1.97	1	0
Complication, Postoperative [description not available]	1.97	1	0
Ocular Infections [description not available]	1.97	1	0
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	1.97	1	0
Eye Infections Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.	1.97	1	0

dimethyldodecylbenzylammonium

Description

Cross-References

Synonyms (109)

Research Excerpts

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (3)

Protein Targets (44)

Potency Measurements

Biological Processes (185)

Molecular Functions (55)

Ceullar Components (41)

Bioassays (127)

Research

Studies (64)

Market Indicators

Research Demand Index: 10.32

Study Types

dimethyldodecylbenzylammonium

Description

Cross-References

Synonyms (109)

Research Excerpts

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (3)

Protein Targets (44)

Potency Measurements

Biological Processes (185)

Molecular Functions (55)

Ceullar Components (41)

Bioassays (127)

Research

Studies (64)

Market Indicators

Research Demand Index: 10.32

Study Types

Related Drugs (77)

Related Conditions (29)